Irritable Bowel Syndrome (IBS) Treatment Market 2025

Irritable Bowel syndrome (IBS) Treatment Market Size

The global irritable bowel syndrome (IBS) treatment market reached a value of nearly $6,877.81 million in 2024, having grown at a compound annual growth rate (CAGR) of 8.49% since 2019. The market is expected to grow from $6,877.81 million in 2024 to $9,888.27 million in 2029 at a rate of 7.53%. The market is then expected to grow at a CAGR of 7.28% from 2029 and reach $14,048.56 million in 2034. Growth in the historic period resulted from rise in the prevalence of irritable bowel syndrome (IBS), growth in preventive healthcare, changing dietary patterns and rising personalized medicine and targeted therapies. Factors that negatively affected growth in the historic period were side effects of IBS medications and regulatory hurdles. Going forward, increasing aging population, increased R&D investments on gut health, growing demand for probiotics and growing adoption of non-pharmacological therapies will drive growth. Factors that could hinder the growth of the irritable bowel syndrome (IBS) treatment market in the future include stigma and lack of awareness high cost of newer therapies and impact of trade war and tariff.

Irritable Bowel syndrome (IBS) Treatment Market Drivers

The key drivers of the irritable bowel syndrome (IBS) treatment market include: Increasing Aging Population During the forecast period, the increasing aging population is expected to propel the growth of the irritable bowel syndrome (IBS) treatment market. As older adults are more susceptible to gastrointestinal disorders due to age-related changes in gut motility, microbiota composition and immune function. This demographic also experiences a higher burden of chronic conditions, such as diabetes and Parkinson’s disease, which can aggravate IBS symptoms. As elderly individuals are more proactive in seeking healthcare, they contribute to higher diagnosis rates and sustained demand for treatment. Moreover, the need for safe and tolerable long-term therapies in this age group encourages the development of age-appropriate drug formulations. Pharmaceutical companies are increasingly targeting geriatric patients with specialized solutions. Together, these factors expand the market potential within the aging population segment. The increasing aging population during the forecast period in 2024 is 1.20%.

Irritable Bowel syndrome (IBS) Treatment Market Restraints

The key restraints on the irritable bowel syndrome (IBS) treatment market include: Stigma And Lack Of Awareness The stigma and lack of awareness is expected to restrict the growth of the irritable bowel syndrome (IBS) treatment market, during the forecast period. Stigma surrounding bowel-related symptoms often prevents individuals from openly discussing their condition or seeking medical help, leading to underdiagnosis and delayed treatment. Many people normalize symptoms like bloating, abdominal pain, or irregular bowel movements, attributing them to lifestyle or diet rather than recognizing them as signs of IBS. This lack of awareness reduces early intervention and limits the demand for specialized treatments. In many regions, especially in low- and middle-income countries, public education about IBS remains minimal, further compounding the issue. Even among healthcare providers, inconsistent diagnostic approaches can lead to misdiagnosis or ineffective treatment. As a result, fewer patients enter the formal treatment pipeline, slowing the overall expansion of the IBS treatment market. Growth affected by stigma and lack of awareness during the forecast period in 2024 is -2.00%.

Irritable Bowel syndrome (IBS) Treatment Market Trends

Major trends shaping the irritable bowel syndrome (IBS) treatment market include: Focus On Launch Of Microbiome-Based IBS Therapies Major companies operating in the irritable bowel syndrome (IBS) treatment market are focusing on microbiome-targeted oral therapies such as EBX‑102‑02, to gain competitive advantage in the market. EBX‑102‑02 is a next‑generation full‑spectrum microbiome drug designed to rebalance gut flora and relieve IBS‑C symptoms. For example, in March 2025, EnteroBiotix, a US‑based clinical‑stage biopharmaceutical company, introduced EBX‑102‑02 in phase 2a trials showing clinically meaningful improvements across multiple symptom domains in IBS‑C patients, including IBS‑Symptom Severity Scale (IBS‑SSS), abdominal pain and stool consistency. This therapy offers target microbiome modulation with oral dosing and favorable tolerability, but outcomes remain preliminary and require larger, longer trials for broader confirmation. Increasing Collaborations to Develop Innovative IBS Treatments Companies in the irritable bowel syndrome (IBS) treatment market are focusing on growing number of partnerships between biopharmaceutical and healthcare companies aimed at advancing new and effective treatment options for irritable bowel syndrome (IBS). Such collaborations combine scientific expertise, innovative technologies, and distribution capabilities to bring safer, well-tolerated, and evidence-based therapies to patients. For example, in March 2025, Immuron Limited, an Australia-based biopharmaceutical company, partnered with Calmino Group AB, a Sweden-based science-driven innovative healthcare company, to jointly develop and commercialize a treatment for irritable bowel syndrome (IBS) in the Australia and New Zealand markets. Immuron will exclusively distribute Calmino’s product ProIBS, a certified medical device designed to alleviate symptoms related to IBS such as abdominal pain, bloating, diarrhea and constipation. ProIBS contains AVH200, derived from Aloe barbadensis Miller, which has gel-forming components that support the intestinal mucosal barrier. This collaboration is intended to improve IBS management and expand Immuron’s product offerings with a scientifically supported, safe and well-tolerated option for patients with IBS symptoms.

Opportunities And Recommendations In The Irritable Bowel syndrome (IBS) Treatment Market

Opportunities – The top opportunities in the irritable bowel syndrome (IBS) treatment market segmented by treatment type will arise in the irritable bowel syndrome – diarrhea-predominant segment, which will gain $1,183.50 million of global annual sales by 2029. The top opportunities in the irritable bowel syndrome (IBS) treatment market segmented by indication will arise in the IBS with diarrhea segment, which will gain $1,327.97 million of global annual sales by 2029. The top opportunities in the irritable bowel syndrome (IBS) treatment market segmented by distribution channel will arise in the online pharmacies segment, which will gain $1,580.11 million of global annual sales by 2029. The top opportunities in the irritable bowel syndrome (IBS) treatment market segmented by end-users will arise in the hospitals segment, which will gain $1,318.75 million of global annual sales by 2029. The irritable bowel syndrome (IBS) treatment market size will gain the most in the USA at $917.30 million. Recommendations- To take advantage of the opportunities, The Business Research Company recommends the irritable bowel syndrome (IBS) treatment companies to focus on advancing microbiome-based oral therapies with clinical validation, focus on personalized nutrition therapies for IBS, focus on expanding digital therapeutics for IBS management, focus on diarrhea-predominant IBS treatments, focus on IBS with constipation segment for growth, expand in emerging markets, continue to focus on developed markets, provide competitively priced offerings, continue to use B2B promotions, focus on strategic partnerships to expand IBS treatment options, focus on online pharmacies to capture growth in the IBS treatment market and focus on homecare settings to drive growth.